Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 4/20 | 0.35 |
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GPR6 | P46095 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589687 | 0.96 | HRH3 (0.35) | HRH3ACHEBCHESIGMAR1CHRM2 | |
| SCHEMBL3590798 | 0.93 | USP14 (0.34) | HRH3ACHEBCHESIGMAR1CHRM2 | |
| SCHEMBL3592187 | 0.93 | BCHE (0.38) | HRH3ACHEBCHESIGMAR1CHRM2 | |
| SCHEMBL3593301 | 0.91 | CNR2 (0.36) | ACHEBCHEGPR6CNR1CNR2 | |
| SCHEMBL3602823 | 0.91 | HRH3 (0.33) | HRH3ACHEBCHESIGMAR1CHRM2 | |
| SCHEMBL3590608 | 0.91 | ACHE (0.37) | ACHEBCHESIGMAR1MEN1KMT2A | |
| SCHEMBL14160082 | 0.90 | PLA2G4A (0.38) | HRH3MEN1KMT2AGPR6 | |
| SCHEMBL3599436 | 0.90 | BCHE (0.37) | ACHEBCHESIGMAR1MEN1KMT2A | |
| SCHEMBL3583725 | 0.89 | HRH3 (0.37) | HRH3ACHEBCHECHRM2GPR6 | |
| SCHEMBL3600425 | 0.89 | OPRK1 (0.39) | ACHEBCHESIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | HRH3 832/4885ACHE 3194/4885BCHE 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.